Fresenius Medical Care : Société Générale – The Premium Review Conference

Societe Generale

The Premium Review

Conference 2022, Paris

December 1, 2022

Q3 2022

© Copyright

Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) Annual Report on Form 20-F under the heading "Forward-Looking Statements" and under the headings in that report referred to therein, and in FMC AG & Co. KGaA's other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.

Implementation of measures as presented herein may be subject to information & consultation procedures with works councils and other employee representative bodies, as per local laws and practice. Consultation procedures may lead to changes on proposed measures.

© Copyright

1

Agenda
2
	3

At a Glance

Strategy & FME25

Financials & Outlook

Investment highlights

Business & Strategy

Leading vertically integrated global dialysis provider

• Largest dialysis network worldwide
• Products serve more than half of the world's dialysis patients
• Leveraging core competencies to expand along the Renal Care Continuum

Growth drivers

Benefitting from solid underlying trends

• Growing and ageing global population
• Increase in chronic diseases
• Transformation of health care systems
• Leading position in
  Value-based Care and Home dialysis
• Leading internal and external innovation pipeline

Sustainability

Embedded in vision, mission and strategy

• Commitment: global standards defined
• Performance: global KPIs and targets for material focus areas
• Transparency: reporting along international standards

FME25

Transformation program enables execution on strategy

• New global operating model to foster strategic clarity, accountability and simplification
• Basis for further sustainable growth
• External reporting to be aligned by 2023
• Sustainable reduction of annual cost base by €500m until 2025

Company Presentation

Q3 2022

Page 4

Leading vertically integrated dialysis provider

Products serving more than half

of the world's dialysis patients

Revenue	3.743
€m

757

19962021

Largest dialysis network worldwide

Revenue	13.876
€m
396
1996	2021

>150 m	~ 50,000	1 out of 2	Products	>4,000	Every 0.6	~345,000	>50 m	Dialysis treat-
dialyzers	dialysis machines	HD patients	available	dialysis	seconds we pro-	dialysis patients	dialysis	ments provided
in 150	in around 50
		worldwide	centers	vide a dialysis		treatments
		treated with an	countries		treatment		p. a.	countries
		FME machine	worldwide

As of December 31, 2021

Company Presentation

Q3 2022

Page 5